Amycretin - the next big thing?

PipNotes

PipNotes

Well-known member
Novo is working on a successor to cagrisema called amycretin, which targets both GLP-1 and amylin receptors. Phase 1b/2a trial showed some encouraging results, upwards of 20% weight reduction. Stock prices jumped about 8%.

www.novonordisk.com
 
22% in roughly 8 months? That's comparable to reta, but with the added amylin receptor activation. I'm guessing we'll see a lot of stacking strategies down the road.

I wonder when we'll see some research options available before big pharma patents lock it all down.
 
Exactly my thoughts. It's time for someone to get to work on amycretin, or MariTide, or whatever other peptides are coming down the line. There's definitely a market for it.
 
I'm curious about the long-term effects of hitting both GLP-1 and amylin receptors simultaneously. We know a fair bit about GLP-1s at this point, but the amylin aspect introduces another layer of complexity. I wonder if there are any concerns about potential feedback loops or desensitization with chronic use?
 
SLU-PP-332 is getting some chatter on other forums too. Interesting to see these new compounds being explored. Some folks are even saying they prefer it over clen and DNP?
 
Interesting point
BigWine said:
I'm curious about the long-term effects of hitting both GLP-1 and amylin receptors simultaneously.
Click to expand...
it's a valid concern. We need more data on the amylin side, especially regarding its impact on satiety and potential for receptor downregulation.
 
Good thoughts
BigWine said:
I'm curious about the long-term effects of hitting both GLP-1 and amylin receptors simultaneously.
Click to expand...
I am wondering if there is a synergistic effect beyond what one might expect from just stacking a GLP-1 with an amylin analogue. We will have to wait and see.
 
You must log in or register to reply here.
Back
Top